- Home
- HYPR vs CTMX Comparison
HYPR vs CTMX Comparison
Compare HYPR & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- CTMX
- Stock Information
- Founded
- HYPR 2014
- CTMX 2008
- Country
- HYPR United States
- CTMX United States
- Employees
- HYPR N/A
- CTMX N/A
- Industry
- HYPR Medical Specialities
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- HYPR Health Care
- CTMX Health Care
- Exchange
- HYPR Nasdaq
- CTMX Nasdaq
- Market Cap
- HYPR 54.6M
- CTMX 60.7M
- IPO Year
- HYPR N/A
- CTMX 2015
- Fundamental
- Price
- HYPR $0.61
- CTMX $2.38
- Analyst Decision
- HYPR Strong Buy
- CTMX Buy
- Analyst Count
- HYPR 3
- CTMX 2
- Target Price
- HYPR $1.13
- CTMX $2.50
- AVG Volume (30 Days)
- HYPR 269.5K
- CTMX 9.5M
- Earning Date
- HYPR 05-13-2025
- CTMX 05-12-2025
- Dividend Yield
- HYPR N/A
- CTMX N/A
- EPS Growth
- HYPR N/A
- CTMX 128.27
- EPS
- HYPR N/A
- CTMX 0.49
- Revenue
- HYPR $11,732,000.00
- CTMX $147,557,000.00
- Revenue This Year
- HYPR $24.00
- CTMX N/A
- Revenue Next Year
- HYPR $28.70
- CTMX N/A
- P/E Ratio
- HYPR N/A
- CTMX $4.90
- Revenue Growth
- HYPR 0.34
- CTMX 23.81
- 52 Week Low
- HYPR $0.58
- CTMX $0.40
- 52 Week High
- HYPR $1.90
- CTMX $2.81
- Technical
- Relative Strength Index (RSI)
- HYPR 35.57
- CTMX 83.13
- Support Level
- HYPR $0.66
- CTMX $0.91
- Resistance Level
- HYPR $0.80
- CTMX $2.55
- Average True Range (ATR)
- HYPR 0.06
- CTMX 0.21
- MACD
- HYPR -0.00
- CTMX 0.18
- Stochastic Oscillator
- HYPR 8.94
- CTMX 91.17
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.